2. Search Result
Search Result
Results for "

CD-1 mice

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

3

Peptides

1

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0277
    Cyproconazole

    		Fungal Others
    Cyproconazole is a triazole fungicide used to protect crops, fruits and vegetables against a wide range of fungal pathogens. Cyproconazole can cause hepatocellular adenomas and carcinomas in CD-1 mice. Cyproconazole also exhibits low toxicity to zebrafish embryos and affects locomotor activity .
    Cyproconazole
  • HY-A0277R
    Cyproconazole (Standard)

    		Reference Standards Fungal Others
    Cyproconazole (Standard) is the analytical standard of Cyproconazole. This product is intended for research and analytical applications. Cyproconazole is a triazole fungicide used to protect crops, fruits and vegetables against a wide range of fungal pathogens. Cyproconazole can cause hepatocellular adenomas and carcinomas in CD-1 mice. Cyproconazole also exhibits low toxicity to zebrafish embryos and affects locomotor activity .
    Cyproconazole (Standard)
  • HY-155478
    Androgen receptor-IN-6

    		Androgen Receptor Cancer
    Androgen receptor-IN-6 (compound 16) is an orally available androgen receptor (Androgen Receptor) potent inhibitor (IC50=0.12 μM in vitro), targeting the disordered N-terminal domain (NTD). Androgen receptor-IN-6 has good Caco2 cell membrane permeability and has an oral activity (F/%) of 16% in male CD-1 mice .
    Androgen receptor-IN-6
  • HY-P1302
    Orphanin FQ(1-11)

    		Opioid Receptor Neurological Disease
    Orphanin FQ(1-11), a orphanin FQ or nociceptin (OFQ/N) fragment, is a potent NOP receptor (ORL-1; OP4) agonist, with a Ki of 55 nM. Orphanin FQ(1-11) has no affinity for μ, δ, κ1 and κ3 receptors (Ki>1000 nM). Orphanin FQ(1-11) is analgesic in CD-1 mice .
    Orphanin FQ(1-11)
  • HY-B0430B
    (±)-Pantothenic acid

    (±)-Pantothenate; (±)-Vitamin B5

    		 Endogenous Metabolite Neurological Disease Metabolic Disease
    (±)-Pantothenic acid ((±)-Pantothenate), a B-vitamin, is an essential vitamin required for the biosynthesis of coenzyme A (CoA) in mammalian cells. Pantothenic acid has protective activity against valproic acid (VPA)-induced neural tube defects (NTD) in CD-1 mice .
    (±)-Pantothenic acid
  • HY-165425
    KR31173

    		Angiotensin Receptor Cardiovascular Disease
    KR31173 is an AT1 antagonist with an IC50 of 3.27  nM. KR31173 can be used as a positron emission tomography (PET) tracer after being labeled with 11C isotope. KR31173 shows promising biodistribution and pharmacological properties in mice. KR31173 selectively binds to organs known to contain a high density of AT1 angiotensin receptors in CD-1 mice .
    KR31173
  • HY-163797
    WRN inhibitor 10

    		DNA/RNA Synthesis Cancer
    WRN inhibitor 10 (Compound P24) is an inhibitor for the Werner helicase WRN with an IC50 of 1.1 nM. WRN inhibitor 10 inhibits the proliferation of cancer cell SW48 with IC50 of 39 nM. WRN inhibitor 10 exhibits good liver microsomal stability and film permeability. WRN inhibitor 10 exhibits good pharmacokinetic characteristics in CD-1 mice .
    WRN inhibitor 10
  • HY-P1302A
    Orphanin FQ(1-11) TFA

    		Opioid Receptor Neurological Disease
    Orphanin FQ(1-11) TFA, a orphanin FQ or nociceptin (OFQ/N) fragment, is a potent NOP receptor (ORL-1; OP4) agonist, with a Ki of 55 nM. Orphanin FQ(1-11) TFA has no affinity for μ, δ, κ1 and κ3 receptors (Ki>1000 nM). Orphanin FQ(1-11) TFA is analgesic in CD-1 mice .
    Orphanin FQ(1-11) TFA
  • HY-163799
    PRMT5-MTA-IN-1

    		Histone Methyltransferase Cancer
    PRMT5-MTA-IN-1 (Compound A9a) is an inhibitor for protein arginine methyltransferase PRMT5-MTA. PRMT5-MTA-IN-1 inhibits the proliferation of colorectal cancer cell HCT116 wildtype and MTAP del mutant, with an IC50 of 16 nM and 2.47 μM. PRMT5-MTA-IN-1 exhibits good liver microsomal stability and film permeability. PRMT5-MTA-IN-1 exhibits good pharmacokinetic characteristics in CD-1 mice .
    PRMT5-MTA-IN-1
  • HY-163816
    Antiproliferative agent-53-d3

    		Cytochrome P450 Cancer
    Antiproliferative agent-53-d3 (Compound C1) is an inhibitor for theta-mediated end joining (TMEJ) in HEK293 cell with an IC50 of 0.14 µM. Antiproliferative agent-53-d3 is the inhibitor for CYP2C19 and CYP2C9 with IC50 of 0.77 and 3.1 µM. Antiproliferative agent-53-d3 inhibits the proliferation of DNA repair-compromised cells, with IC50 of 8.1 µM for BRCA2 -/- DLD-1. Antiproliferative agent-53-d3 exhibits good pharmacokinetic characteristics in CD-1 mice .
    Antiproliferative agent-53-d3
  • HY-158435
    P-gp inhibitor 23

    		P-glycoprotein Cytochrome P450 Cancer
    P-gp inhibitor 23 (compound 14F) is a potent inhibitor of P-gp and CYP3A4, with the EC50 and IC50 of 28 nM and 223 nM, respectively .
    P-gp inhibitor 23
  • HY-158701
    KRAS G12D inhibitor 23

    		Ras Cancer
    KRAS G12D inhibitor 23 (compound 46-3) is a potent inhibitor of KRAS G12D, with the IC50 of 0.007 μM. KRAS G12D inhibitor 23 plays an important role in cancer research .
    KRAS G12D inhibitor 23
  • HY-P10027A
    Clovibactin TFA

    		Antibiotic Bacterial Infection
    Clovibactin TFA is the TFA salt form of Clovibactin (HY-P10027). Clovibactin TFA is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors .
    Clovibactin TFA
  • HY-106817
    Amitivir

    LY 217896

    		 Influenza Virus Infection
    Amitivir (LY 217896), a thiadiazole derivative, possesses broad antiviral activity against orthomyxo- and paramyxoviruses. Amitivir is effective against influenza A and B viruses .
    Amitivir
  • HY-176241
    DC-174

    		Others Cardiovascular Disease
    DC-174 is an orally active inhibitor of snake venom metalloproteinases (SVMP) with a broad spectrum of inhibitory activity against a variety of snake venom SVMPs. DC-174 acts directly on the active site of SVMPs via zinc-binding groups, inhibiting their enzymatic activity and procoagulant toxicity. DC-174 can significantly prolong the survival time of mice attacked by snake venom. DC-174 can be used in the study of first aid for snake bites .
    DC-174
  • HY-158706
    SAE-IN-2

    		E1/E2/E3 Enzyme Cancer
    SAE-IN-2 (compound 6) is a potent inhibitor of sumo activating enzume (SAE), with the IC50 of 27.8 nM .
    SAE-IN-2
  • HY-176205
    Ligritinib

    AB801

    		 TAM Receptor Cancer
    Ligritinib (AB801) is an orally active AXL receptor tyrosine kinase inhibitor. Ligritinib blocks the downstream signaling pathway by inhibiting the kinase activity of AXL. Ligritinib can be used in cancer research, especially in combination with chemotherapy for non-small cell lung cancer (NSCLC) .
    Ligritinib
  • HY-163540
    NP-BTA

    		Aminoacyl-tRNA Synthetase Fungal Infection
    NP-BTA is an allosteric inhibitor for glutaminyl-tRNA synthetase (GlnRS). NP-BTA exhibits antifungal efficacy against Candida albicans, with MIC50 of 6.25 μM .
    NP-BTA
  • HY-137439
    Fanotaprim

    VYR-006

    		 Antifolate Infection
    Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor with IC50s of 1.57 and 308 nM for tgDHFR (Toxoplasma gondii DHFR) and hDHFR (human DHFR), respectively. Fanotaprim has the potential for the research of toxoplasmosis .
    Fanotaprim
  • HY-162629
    LDHA-IN-7

    		Lactate Dehydrogenase Cancer
    LDHA-IN-7 (compound 21) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA) and LDHB, with the IC50s of 72 nM and 1.2 Μm, respectively .
    LDHA-IN-7
  • HY-174381
    BChE-IN-41

    		Cholinesterase (ChE) Amyloid-β Tau Protein Neurological Disease
    BChE-IN-41 is a highly selective Butyrylcholinesterase (BChE) inhibitor (IC50 =12 nM, Ki = 6.6 nM). BChE-IN-41 has high brain penetration with a brain-to-plasma ratio of 9.0. BChE-IN-41 has pro-cognitive effects on mice with AD-like symptoms induced by Scopolamine (HY-N0296) and Aβ1-42 .
    BChE-IN-41
  • HY-173302
    sEH inhibitor-20

    		Epoxide Hydrolase Neurological Disease
    sEH inhibitor-20 is an orally active and metabolically stable sEH inhibitor (IC50: 0.2 nM). sEH inhibitor-20 has significant analgesic and anti-inflammatory activities and is expected to become a potential candidate compound for the study of neuropathic pain .
    sEH inhibitor-20
  • HY-142295
    GNF2133
    1 Publications Verification

    		 DYRK Metabolic Disease
    GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes .
    GNF2133
  • HY-142295A
    GNF2133 hydrochloride

    		DYRK Metabolic Disease
    GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 hydrochloride significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 hydrochloride has the potential for the research of type 1 diabetes .
    GNF2133 hydrochloride
  • HY-A0106R
    Levamisole (Standard)

    (-)-Tetramisole (Standard)

    		 Reference Standards nAChR Parasite Infection Inflammation/Immunology Cancer
    Levamisole (Standard) is the analytical standard of Levamisole. This product is intended for research and analytical applications. Levamisole ((-)-Levamisole), an anthelmintic agent with immunomodulatory properties. Levamisole acts as a positive allosteric modulator (PAM) for the α3β2 (EC50=300 μM) and α3β4 (EC50=100 μM) subtype of nAChRs. Orally active .
    Levamisole (Standard)
  • HY-A0106
    Levamisole
    Maximum Cited Publications
    6 Publications Verification

    (-)-Tetramisole

    		 nAChR Parasite Infection Inflammation/Immunology Cancer
    Levamisole ((-)-Levamisole), an anthelmintic agent with immunomodulatory properties. Levamisole acts as a positive allosteric modulator (PAM) for the α3β2 (EC50=300 μM) and α3β4 (EC50=100 μM) subtype of nAChRs. Orally active .
    Levamisole
  • HY-172661
    Kylo-0603

    		Thyroid Hormone Receptor Interleukin Related LDLR Infection Metabolic Disease
    KYLO-0603 is an orally active, selective THR-β agonist (EC50: 31.07 nM). KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research .
    Kylo-0603
  • HY-162727
    GCS-12

    		IFNAR Interleukin Related CD1 Inflammation/Immunology Cancer
    GCS-12 is a Th1/2-balanced sulfonamide glycolipid with improved interaction with CD1d. GCS-12 is an agonist for natural killer T (NKT) cell, that induces the secretion of cytokine IFN-γ and IL-4, and exhibits immunomodulatory and anti-tumor activities in mice .
    GCS-12
  • HY-150080
    GSK3739936

    BMS-986180

    		 HIV HIV Integrase Infection
    GSK3739936 (BMS-986180) is a potent HIV-1 allosteric integrase inhibitor with an IC50 value of 11.1 nM and an EC50 value of 1.7 nM. GSK3739936 is also a weak CYP inhibitor (IC50>24.3 μM). GSK3739936 shows favorable pharmacokinetic property in preclinical species with rapid absorption, low to moderate clearance and excellent oral bioavailability .
    GSK3739936
  • HY-B0973
    Dibenzothiophene

    DBT; Diphenylene sulfide

    		 Cytochrome P450 Aryl Hydrocarbon Receptor Metabolic Disease
    Dibenzothiophene is an orally active and a noncompetitive CYP1A inhibitor. Dibenzothiophene inhibits CYP1A-mediated EROD activity with a Km of 0.592 μM. Dibenzothiophene interacts with the AHR pathway. Dibenzothiophene enhances the embryotoxicity of β-naphthoflavone (HY-114740). Dibenzothiophene shows acute toxicity in mice. Dibenzothiophene is mainly used for the study of the mechanism of developmental toxicity in organisms .
    Dibenzothiophene
  • HY-120382
    LY 215890

    		Bacterial Infection
    LY 215890 ia an orally active antibacterial agent aganist Escherichia coli EC14 and Klebsiella pneumonia X26 .
    LY 215890
  • HY-143411
    GEM144

    		HDAC Apoptosis DNA/RNA Synthesis Cancer
    GEM144 is a potent and orally active DNA polymerase α (POLA1) and HDAC 11 dual inhibitor. GEM144 induces acetylation of p53, activation of p21, G1/S cell cycle arrest, and apoptosis. GEM144 has significant antitumor activity in human orthotopic malignant pleural mesothelioma xenografts .
    GEM144
  • HY-120717
    VU6001966

    		mGluR Others
    VU6001966 (compound 15m) is a potent and cross the blood-brain barrier mGlu2 (metabotropic glutamate receptor 2) negative allosteric modulator with IC50s of 78 nM and >30 µM for mGlu2 and mGlu3, respectively. VU6001966 can serve as an mGlu2 PET tracer .
    VU6001966
  • HY-147712
    PKC-IN-4

    		PKC Inflammation/Immunology
    PKC-IN-4 (compound 7l) is a potent and orally active aPKC inhibitor with an IC50 of 0.52 µM. PKC-IN-4 inhibits TNF-α induced NF-κB activity in vitro. PKC-IN-4 blocks VEGF- and TNFα-induced permeability across the retinal vasculature .
    PKC-IN-4
  • HY-122895A
    (E/Z)-E64FC26

    		Apoptosis PDI Cancer
    (E/Z)-E64FC26 is a mixture complex of E-E64FC26 and Z-E64FC26. E64FC26 (E-E64FC26) is a potent pan-inhibitor of the protein disulfide isomerase (PDI) family, with IC50s of 1.9, 20.9, 25.9, 16.3, and 25.4 μM against PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6. E64FC26 shows anti-myeloma activity .
    (E/Z)-E64FC26
  • HY-122895
    E64FC26
    2 Publications Verification

    		 Apoptosis PDI Cancer
    E64FC26 is a potent pan-inhibitor of the protein disulfide isomerase (PDI) family, with IC50s of 1.9, 20.9, 25.9, 16.3, and 25.4 μM against PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6, respectively. E64FC26 shows anti-myeloma activity .
    E64FC26

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: